Mammary Cell News Volume 13.04 | Feb 4 2021

    0
    100







    2021-02-4 | MCN 15.04


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.04 – 4 February, 2021
    TOP STORY

    CD39+PD-1+CD8+ T Cells Mediate Metastatic Dormancy in Breast Cancer

    Scientists identified a discrete population of CD39+PD-1+CD8+ T cells in primary tumors and in dormant metastasis, which is hardly found in aggressively metastasizing tumors.
    [Nature Communications]

    Full Article

    Explore scientific events this February with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    Activation of the Interferon Signaling Pathway Is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

    Parental breast cancer cells and their endocrine-resistant derivatives were used. Derivatives with acquired resistance to palbociclib were generated from parental and estrogen-deprivation resistant MCF7 and T47D cells.
    [Clinical Cancer Research]

    Abstract

    MiR-211 Determines Brain Metastasis Specificity through SOX11/NGN2 Axis in Triple-Negative Breast Cancer

    A high level of miR-211 could act as a brain metastatic prognostic marker in vivo. SOX11 and NGN2 were the downstream targets of miR-211 and negatively regulated miR-211-mediated TNBC brain metastasis in vitro and in vivo.
    [Oncogene]

    Full Article

    Transcriptional Coregulator NUPR1 Maintains Tamoxifen Resistance in Breast Cancer Cells

    In tamoxifen-resistant ESR1 breast cancer cells, NUPR1 depletion resulted in premature senescence in vitro and tumor suppression in vivo.
    [Cell Death & Disease]

    Full Article

    The Bovine Dialysable Leukocyte Extract IMMUNEPOTENT CRP Induces Immunogenic Cell Death in Breast Cancer Cells Leading to Long-Term Antitumor Memory

    Researchers evaluated if IMMUNEPOTENT CRP induced immunogenic cell death in breast cancer cells.
    [British Journal of Cancer]

    Abstract

    Lipidome-Based Targeting of STAT3-Driven Breast Cancer Cells Using Poly-L-Glutamic Acid-Coated Layer-by-Layer Nanoparticles

    Scientists found that poly-L-glutamic acid (PLE)-coated nanoparticles (NPs) bond to STAT3-transformed breast cancer cells with 50% greater efficiency than to non-transformed cells, and the heightened PLE-NP binding to TNBC cells was attenuated by STAT3 inhibition.
    [Molecular Cancer Therapeutics]

    Abstract

    G3BP1 Promotes Human Breast Cancer Cell Proliferation through Coordinating with GSK-3β and Stabilizing β-Catenin

    The authors report that Ras-GTPase activating SH3 domain-binding protein 1 (G3BP1) was upregulated and correlated with poor prognosis in breast cancer.
    [Acta Pharmacologica Sinica]

    Abstract

    m6A-Induced LINC00958 Promotes Breast Cancer Tumorigenesis via the miR-378a-3p/YY1 Axis

    LINC00958 was markedly overexpressed in breast cancer (BC) tissue and cells, and LINC00958 upregulation promoted the tumor progression of BC cells.
    [Cell Death Discovery]

    Full Article

    Evaluation of Quasi-Static and Dynamic Nanomechanical Properties of Bone-Metastatic Breast Cancer Cells Using a Nanoclay Cancer Testbed

    The authors report evaluation of mechanical properties of two breast cancer cells with different metastatic ability at the site of bone metastases, using quasi-static and dynamic nanoindentation methods.
    [Scientific Reports]

    Full Article

    The Mitotic Checkpoint Is a Targetable Vulnerability of Carboplatin-Resistant Triple Negative Breast Cancers

    Investigators generated carboplatin-resistant TNBC MDA-MB-468 cell line and patient derived TNBC xenograft models.
    [Scientific Reports]

    Full Article

    Request a free copy of the Growing Organoids from Stem Cells Wallchart
    REVIEWS

    Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

    Scientists present a comprehensive review of the current applications and preclinical studies of various actively targeted nanoparticles for specific delivery of different chemotherapeutics agents used for the management of breast cancer.
    [Biomedicines]

    Full Article

    INDUSTRY AND POLICY NEWS

    Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

    Atossa Therapeutics, Inc. announced updated findings following 26 months of Expanded Access single-patient studies of Atossa’s Endoxifen.
    [Atossa Therapeutics, Inc.]

    Press Release

    FEATURED EVENT

    Wisconsin Stem Cell Symposium: The Single Cell Revolution in Stem Cells

    April 14, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Academic Surgical Pathologist – Breast Pathology

    University of Nebraska Medical Center – Omaha, Nebraska, United States

    Postdoctoral Researcher – Somatic Mutations in Ribosomal Proteins in Cancer

    KU Leuven – Leuven, Belgium

    Medical Scientist – Breast Cancer

    Gilead Sciences, Inc. – London, England, United Kingdom

    Director – Medical Affairs Breast Cancer

    Gilead Sciences, Inc. – Munich, Germany

    Postdoctoral Fellow – Tumor Biology and Therapeutic Applications

    Harvard Medical School – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter